{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T18:25:10Z","timestamp":1786904710195,"version":"build-2736575974"},"reference-count":69,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Palliative Medicine"],"abstract":"<jats:p>Stimulant use disorder (StUD) is common in the hospice and palliative care (PC) setting, though guidance for clinicians remains limited. Stigma around stimulant use is widespread and can lead to impaired clinician\/patient communication, poor symptom control, and lower quality of care. PC clinicians should be able to diagnose StUD, understand the potential pharmacologic and nonpharmacologic management options, engage with patients in a trauma-informed way, and refer to addiction medicine colleagues when appropriate. When utilizing opioids for pain management, PC clinicians should be aware of the impact of stimulant use on opioid risk and toxicity. In this article, a multidisciplinary group of PC, hospice, addiction medicine, psychiatry, ethics, and pharmacy clinicians presents ten practical tips for caring for seriously ill patients with current or prior StUD.<\/jats:p>","DOI":"10.1177\/10966218261478398","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:27:34Z","timestamp":1786685254000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Top Ten Tips Palliative Care Clinicians Should Know when Caring for Seriously Ill Patients with Stimulant Use Disorders"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0209-8481","authenticated-orcid":false,"given":"Rebekka","family":"DePew","sequence":"first","affiliation":[{"name":"Division of Palliative Medicine, Department of Family and Preventative Medicine, Emory University School of Medicine and Grady Memorial Hospital, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6423-3087","authenticated-orcid":false,"given":"Nicole","family":"Dussault","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Quirk","sequence":"additional","affiliation":[{"name":"Division of Palliative Care, Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA."},{"name":"Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Vipler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Borris","sequence":"additional","affiliation":[{"name":"Division of Palliative Care, Department of Medicine, MedStar Harbor Hospital, Baltimore, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"DiScala","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Thomas H. Corey VA Medical Center, West Palm Beach, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teddy","family":"Scheel","sequence":"additional","affiliation":[{"name":"Oncology Social Work Department, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-8093","authenticated-orcid":false,"given":"Katrina","family":"Nickels","sequence":"additional","affiliation":[{"name":"Division of Palliative &amp; Supportive Care, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-7368","authenticated-orcid":false,"given":"Gregg","family":"Robbins-Welty","sequence":"additional","affiliation":[{"name":"Division of Palliative Medicine, Department of Family and Preventative Medicine, Emory University School of Medicine and Grady Memorial Hospital, Atlanta, Georgia, USA."},{"name":"Departments of Psychiatry and Behavioral Sciences and Medicine, Emory University School of Medicine, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Palliative Medicine, Department of Medicine, UCSF, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2864"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2012.07.043"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7432a1"},{"key":"e_1_3_2_5_1","unstructured":"4.Substance Abuse and Mental Health Services Administration (SAMHSA). Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. 2025. Available from: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt56287\/2024-nsduh-annual-national-report.pdf"},{"issue":"1","key":"e_1_3_2_6_1","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2017\u20132023","author":"Garnett MF","year":"2026","unstructured":"5.Garnett MF, , Cisewski JA, , Ahmad FB. Drugs most frequently involved in drug overdose deaths: United States, 2017\u20132023. Natl Vital Stat Rep 2026(1):1.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_2_7_1","first-page":"1","article-title":"Interactions between opioids and stimulants: Behavioral pharmacology of abuse-related effects","volume":"93","author":"Maguire DR","year":"2022","unstructured":"6.Maguire DR, , Minervini V. Interactions between opioids and stimulants: Behavioral pharmacology of abuse-related effects. Adv Pharmacol 2022;93:1\u201333.","journal-title":"Adv Pharmacol"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S337338"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05563-3"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd007380"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113482532"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121793"},{"key":"e_1_3_2_13_1","volume-title":"Treatment for Stimulant Use Disorders: Updated 2021 [Internet]","year":"1999","unstructured":"12.Chapter 2\u2014How Stimulants Affect the Brain and Behavior. In: Treatment for Stimulant Use Disorders: Updated 2021 [Internet]. Substance Abuse and Mental Health Services Administration (US); 1999. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576548\/"},{"key":"e_1_3_2_14_1","unstructured":"13.Terminology and Information on Drugs. United Nations: Office on Drugs and Crime. Available from: https:\/\/www.unodc.org\/unodc\/en\/scientists\/terminology-and-information-on-drugs_new.html [Last accessed: July7 2026]."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/27.6.1181"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28134969"},{"key":"e_1_3_2_17_1","volume-title":"Goldfrank\u2019s Toxicologic Emergencies","author":"Murray L","year":"2004","unstructured":"16.Murray L. Goldfrank\u2019s Toxicologic Emergencies, 7th ed. McGraw-Hill Companies; 2004.","edition":"7"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4212-2"},{"key":"e_1_3_2_19_1","unstructured":"18.Highlights Of Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208510lbl.pdf [Last accessed: July7 2026]."},{"key":"e_1_3_2_20_1","unstructured":"19.PROVIGIL\u00ae (modafinil) Tablets [C-IV]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020717s020s013s018lbl.pdf [Last accessed: July7 2026]."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.940569"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-S1-43"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15242"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.130"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12060782"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108114"},{"key":"e_1_3_2_28_1","first-page":"1","article-title":"The ASAM\/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder","volume":"18","author":"Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team","year":"2024","unstructured":"27.Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team. The ASAM\/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. J Addict Med 2024;18:1\u201356.","journal-title":"J Addict Med"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20250053"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.2196\/80808"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0017542"},{"issue":"2","key":"e_1_3_2_32_1","first-page":"CD011866","article-title":"Psychosocial interventions for stimulant use disorder","volume":"2","author":"Minozzi S","year":"2024","unstructured":"31.Minozzi S, , Saulle R, , Amato L, et al. Psychosocial interventions for stimulant use disorder. Cochrane Database Syst Rev 2024;2(2):CD011866.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000218"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.3655"},{"key":"e_1_3_2_35_1","unstructured":"34.WELLBUTRIN XL\u00ae Information for Prescribers. Available from: https:\/\/www.wellbutrinxl.com\/for-prescribers\/ [Last accessed: May30 2026]."},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234809"},{"key":"e_1_3_2_37_1","unstructured":"36.Stimulants. DEA. Available from: https:\/\/www.dea.gov\/factsheets\/stimulants [Last accessed: June6 2026]."},{"key":"e_1_3_2_38_1","volume-title":"Treatment for Stimulant Use Disorders: Updated 2021","year":"1999","unstructured":"37.Chapter 5\u2014Practical Application of Treatment Strategies. In: Treatment for Stimulant Use Disorders: Updated 2021. Substance Abuse and Mental Health Services Administration (US); 1999. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576542\/"},{"issue":"9","key":"e_1_3_2_39_1","first-page":"e45995","article-title":"Adverse Effects of Stimulant Interventions for Attention Deficit Hyperactivity Disorder (ADHD): A comprehensive systematic review","volume":"15","author":"Nanda A","year":"2023","unstructured":"38.Nanda A, , Janga LSN, , Sambe HG, et al. Adverse Effects of Stimulant Interventions for Attention Deficit Hyperactivity Disorder (ADHD): A comprehensive systematic review. Cureus 2023;15(9):e45995.","journal-title":"Cureus"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13080899"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15050424"},{"key":"e_1_3_2_42_1","unstructured":"41.National Harm Reduction Coalition. Principles of Harm Reduction. Available from: https:\/\/harmreduction.org\/about-us\/principles-of-harm-reduction\/"},{"key":"e_1_3_2_43_1","unstructured":"42.The Truth About Harm Reduction\u2014Facts from. SAFE Project; 2021. Available from: https:\/\/www.safeproject.us\/resource\/the-truth-about-harm-reduction\/ [Last accessed: May29 2026]."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0178"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16409"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-024-01395-z"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2019.1697283"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000824"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2022.05.004"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157656"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.050880"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.010273"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2022.0399"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf326"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34921"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0032"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.06.022"},{"key":"e_1_3_2_58_1","unstructured":"57.VA\/DOD. Clinical Practice Guidelines. Available from: https:\/\/www.healthquality.va.gov\/guidelines\/pain\/cot\/ [Last accessed: June7 2026]."},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2021.0378"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00910-8"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/02692163211015567"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.05031.x"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12699"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000323"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2026.1163"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114868"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909118806664"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951523001402"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.0263"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-002906"}],"container-title":["Journal of Palliative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10966218261478398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10966218261478398","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10966218261478398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T17:49:42Z","timestamp":1786902582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10966218261478398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":69,"alternative-id":["10.1177\/10966218261478398"],"URL":"https:\/\/doi.org\/10.1177\/10966218261478398","relation":{},"ISSN":["1096-6218","1557-7740"],"issn-type":[{"value":"1096-6218","type":"print"},{"value":"1557-7740","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"10966218261478398"}}